Position Statement from the Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), the Polish Society of Andrology, and the International Scientific Association for the Supp
It is the recommendation of the Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), the Polish Society of Andrology, and the International Scientific Association for the Support and Development of Medical Technologies that MI be considered in pretreatment strategies prior to ovarian hyperstimulation with gonadotropins.
The use of MI has been demonstrated to at the very least reduce gonadotropin use and duration in both non-PCOS and PCOS patient groups, thus reducing patient exposure to excessive levels of gonadotropin; in addition, it may potentially result in financial savings for ART procedures.
Furthermore, the use of MI in IVF-ET may also increase oocyte and embryo quality, in addition to increasing fertilization rate and pregnancy outcomes. It should also be noted that MI has a well-established safety and tolerability profile, making it an ideal candidate for routine use, with minimal risk.
In non-PCOS and PCOS populations, it is advised that MI (4 g) + folic acid (400 µg) supplementation be started three months prior to the start of COH. It is also recommended that treatment be continued throughout pregnancy, as MI can be beneficial in reducing the risk of gestational complications [54]. In PCOS populations with obesity, the use of MI and DCI in a 40:1 ratio may be considered; however, further study is required to establish the efficacy of this supplementation regime.
Lastly, while MI may be effective in ICSI procedures for male factor infertility, more evidence is required. These recommendations are in line with the recently published NICE-adapted guidelines from the Italian Society of Human Reproduction, who stated “Consider prescribing MI prior to IVF because it can reduce the total dose of administered gonadotropins”.
Full content: https://www.mdpi.com/2077-0383/14/2/558
